A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
A phase 1/2 trial of Will receive HH-009 injection 20 mg/kg, Q3W in hepatocellular carcinoma, run by Huahui Health, now recruiting.
Overview
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC is a phase 1/2 interventional study registered as NCT07547553 by Huahui Health, with 30 participants planned, started 2026-05-19 and due to reach its primary completion in 2028-10-30. Interventions recorded: Will receive HH-009 injection 20 mg/kg, Q3W and Will receive HH-009 injection 30 mg/kg, Q3W.
Similar pages
not linked directly; found by shared links- TrialA Study of PTX-9908 Injection for Non-resectable HCC with TACE
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialGPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialTo Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialA Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialNWRD06 DNA Plasmid for HCC After Curative Resection.
Shares Hepatocellular carcinoma and the tag pipeline.